ANDREW L FELDMAN, M.D.
Medical Practice at 1 St, Rochester, MN
License number
Minnesota 102499
Category
Medical Practice
Type
Anatomic Pathology & Clinical Pathology
Address
Address
200 1St St SW, Rochester, MN 55905
Phone
(507) 284-2511
Professional information
Andrew L Feldman, Rochester MN
Specialties:
Pathologist
Address:
200 1St St Sw, Rochester, MN 55905
Education:
Doctor of Medicine
Board certifications:
American Board of Pathology Certification in Anatomic Pathology (Pathology), American Board of Pathology Sub-certificate in Hematology (Pathology)
Dr. Andrew L Feldman, Rochester MN - MD (Doctor of Medicine)
Specialties:
Hematology, Hematopathology
Address:
Mayo Clinic
200 1St St SW, Rochester 55905
(507) 284-2511 (Phone)
200 1St St SW, Rochester 55905
(507) 284-2511 (Phone)
Certifications:
Anatomic Pathology, 2004, Hematology & Pathology, 2006
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Mayo Clinic
200 1St St SW, Rochester 55905
Mayo Clinic Saint Marys Hospital
1216 2Nd St South #West, Rochester 55902
North Memorial Medical Center
3300 Oakdale Ave North, Robbinsdale 55422
200 1St St SW, Rochester 55905
Mayo Clinic Saint Marys Hospital
1216 2Nd St South #West, Rochester 55902
North Memorial Medical Center
3300 Oakdale Ave North, Robbinsdale 55422
Education:
Medical School
Brown University / Alpert Medical School
Brown University / Alpert Medical School
Reducing Irf4, Dusp22, Or Flj43663 Polypeptide Expression
US Patent:
2011030, Dec 15, 2011
Filed:
Aug 19, 2011
Appl. No.:
13/213390
Inventors:
Andrew L. Feldman - Rochester MN, US
Ahmet Dogan - Rochester MN, US
George Vasmatzis - Oronoco MN, US
Mark Law - Rochester MN, US
David I. Smith - Rochester MN, US
Ahmet Dogan - Rochester MN, US
George Vasmatzis - Oronoco MN, US
Mark Law - Rochester MN, US
David I. Smith - Rochester MN, US
Assignee:
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH - Rochester MN
International Classification:
C40B 30/04, C12Q 1/42, G01N 33/573, C12Q 1/68
US Classification:
506 9, 435 618, 435 21, 435 71
Abstract:
This document relates to the activity of interferon regulatory factor 4 (IRF4) in T-cell lymphomas. For example, methods and materials involved in reducing the expression of an IRF4 polypeptide in T-cell lymphoma cells and identifying agents having the ability to reduce expression of an IRF4 polypeptide in T-cell lymphoma cells are provided. This document also relates to reducing DUSP22 or FLJ43663 polypeptide activity in T-cell lymphomas. For example, methods and materials involved in reducing the expression of DUSP22 polypeptides and/or FLJ43663 polypeptides in T-cell lymphoma cells and identifying agents having the ability to reduce expression of DUSP22 polypeptides and/or FLJ43663 polypeptides in T-cell lymphoma cells are provided.
Reducing Irf4, Dusp22, Or Flj43663 Polypeptide Expression
US Patent:
2010032, Dec 23, 2010
Filed:
May 18, 2010
Appl. No.:
12/782484
Inventors:
Andrew L. Feldman - Rochester MN, US
Ahmet Dogan - Rochester MN, US
George Vasmatzis - Oronoco MN, US
Mark Law - Rochester MN, US
David I. Smith - Rochester MN, US
Ahmet Dogan - Rochester MN, US
George Vasmatzis - Oronoco MN, US
Mark Law - Rochester MN, US
David I. Smith - Rochester MN, US
Assignee:
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH - Rochester MN
International Classification:
A61K 31/713, C12Q 1/68, G01N 33/68, A61P 35/00
US Classification:
514 44 A, 435 6, 435 71
Abstract:
This document relates to the activity of interferon regulatory factor 4 (IRF4) in T-cell lymphomas. For example, methods and materials involved in reducing the expression of an IRF4 polypeptide in T-cell lymphoma cells and identifying agents having the ability to reduce expression of an IRF4 polypeptide in T-cell lymphoma cells are provided. This document also relates to reducing DUSP22 or FLJ43663 polypeptide activity in T-cell lymphomas. For example, methods and materials involved in reducing the expression of DUSP22 polypeptides and/or FLJ43663 polypeptides in T-cell lymphoma cells and identifying agents having the ability to reduce expression of DUSP22 polypeptides and/or FLJ43663 polypeptides in T-cell lymphoma cells are provided.